Associations - Myelodysplastic Syndrome

CANCER:

Myelodysplastic Syndrome

No biomarker No biomarker	Myelodysplastic Syndrome MDS	decitabine/cedazuridine Sensitive: A1 - Approval decitabine/cedazuridine Sensitive : A1
No biomarker No biomarker	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A1 - Approval luspatercept-aamt Sensitive : A1
Chr del(5q) Chr del(5q)	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker No biomarker	Myelodysplastic Syndrome MDS	azacitidine Sensitive: A1 - Approval azacitidine Sensitive : A1
No biomarker No biomarker	Myelodysplastic Syndrome MDS	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1
CALR mutation CALR mutation	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2
CALR mutation CALR mutation	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
MPL W515L MPL W515L	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2
MPL W515L MPL W515L	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
JAK2 V617F JAK2 V617F	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2
SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	luspatercept-aamt Sensitive: A2 - Guideline luspatercept-aamt Sensitive : A2
JAK2 V617F JAK2 V617F	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
SF3B1 mutation SF3B1 mutation	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	APR-246 Sensitive: B - Late Trials APR-246 Sensitive : B
No biomarker No biomarker	Myelodysplastic Syndrome MDS	Hu5F9-G4 Sensitive: B - Late Trials Hu5F9-G4 Sensitive : B
DNMT3A mutation + SF3B1 mutation DNMT3A mutation + SF3B1 mutation	Myelodysplastic Syndrome MDS	lenalidomide Resistant: B - Late Trials lenalidomide Resistant : B
No biomarker No biomarker	Myelodysplastic Syndrome MDS	MLN4924 Sensitive: B - Late Trials MLN4924 Sensitive : B
No biomarker No biomarker	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
Chr del(5)(q31) Chr del(5)(q31)	Myelodysplastic Syndrome MDS	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
BCR-ABL1 fusion BCR-ABL1 fusion	Myelodysplastic Syndrome MDS	imatinib Sensitive: C1 - Off-label imatinib Sensitive : C1
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	venetoclax Sensitive: C1 - Off-label venetoclax Sensitive : C1
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	CB-839 Sensitive: C2 – Inclusion Criteria CB-839 Sensitive : C2
FLT3 mutation FLT3 mutation	Myelodysplastic Syndrome MDS	ARO-002 Sensitive: C2 – Inclusion Criteria ARO-002 Sensitive : C2
TP53 mutation TP53 mutation	Myelodysplastic Syndrome MDS	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES